Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

Open access
De Backer, Ole, Dangas, George D., Jilaihawi, Hasan, Leipsic, Jonathon A., Terkelsen, Christian J., Makkar, Raj, Kini, Annapoorna S., Veien, Karsten T., Abdel-Wahab, Mohamed, Kim, Won-Keun, Balan, Prakash, Van Mieghem, Nicolas, Mathiassen, Ole N., Jeger, Raban V., Arnold, Martin, Mehran, Roxana, Guimarães, Ana H.C., Nørgaard, Bjarne L., Kofoed, Klaus F., Blanke, Philipp, Windecker, Stephan, Søndergaard, Lars·2020·New England Journal of Medicine

Abstract

BACKGROUND: Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not known. METHODS: In a substudy of a large randomized trial, we randomly assigned patients who had undergone successful TAVR and who did not have an indication for long-term anticoagulation to a rivaroxaban-based antithrombotic strategy (rivaroxaban [10 mg] plus aspirin [75 to 100 mg] once daily) or an antiplatelet-based strategy (clopidogrel [75 mg] plus aspirin [75 to 100 mg] once daily). Patients underwent evaluation by four-dimensional CT at a mean (±SD) of 90±15 days after randomization. The primary end point was the percentage of patients with at least one prosthetic valve leaflet with grade 3 or higher motion reduction (i.e., involving >50% of the leaflet). Leaflet thickening was also assessed. RESULTS: A total of 231 patients were enrolled. At least one prosthetic valve leaflet with grade 3 or higher motion reduction was found in 2 of 97 patients (2.1%) who had scans that could be evaluated in the rivaroxaban group, as compared with 11 of 101 (10.9%) in the antiplatelet group (difference, -8.8 percentage points; 95% confidence interval [CI], -16.5 to -1.9; P = 0.01). Thickening of at least one leaflet was observed in 12 of 97 patients (12.4%) in the rivaroxaban group and in 33 of 102 (32.4%) in the antiplatelet group (difference, -20.0 percentage points; 95% CI, -30.9 to -8.5). In the main trial, the risk of death or thromboembolic events and the risk of life-threatening, disabling, or major bleeding were higher with rivaroxaban (hazard ratios of 1.35 and 1.50, respectively). CONCLUSIONS: In a substudy of a trial involving patients without an indication for long-term anticoagulation who had undergone successful TAVR, a rivaroxaban-based antithrombotic strategy was more effective than an antiplatelet-based strategy in preventing subclinical leaflet-motion abnormalities. However, in the main trial, the rivaroxaban-based strategy was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than the antiplatelet-based strategy. (Funded by Bayer; GALILEO-4D ClinicalTrials.gov number, NCT02833948.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1911426

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 293

Metadata

Authors
De Backer, O., Dangas, G. D., Jilaihawi, H., Leipsic, J. A., Terkelsen, C. J., Makkar, R., Kini, A. S., Veien, K. T., Abdel-Wahab, M., Kim, W.-K., Balan, P., Van Mieghem, N., Mathiassen, O. N., Jeger, R. V., Arnold, M., Mehran, R., Guimarães, A. H. C., Nørgaard, B. L., Kofoed, K. F., Blanke, P., Windecker, S., & Søndergaard, L.
Venue
New England Journal of Medicine
Published
2020-01-09
Volume
382
Issue
2
Pages
130-139
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2982829887
Cited by
293
References
27
FWCI
28.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. https://app.cochat.ai/papers/10.1056/nejmoa1911426
The paper
De Backer, O., Dangas, G. D., Jilaihawi, H., Leipsic, J. A., Terkelsen, C. J., Makkar, R., Kini, A. S., Veien, K. T., Abdel-Wahab, M., Kim, W.-K., Balan, P., Van Mieghem, N., Mathiassen, O. N., Jeger, R. V., Arnold, M., Mehran, R., Guimarães, A. H. C., Nørgaard, B. L., Kofoed, K. F., . . . Søndergaard, L. (2020). Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1911426

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.